See more : Share India Securities Limited (SHAREINDIA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Baudax Bio, Inc. (BXRXQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Baudax Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Empresa Metropolitana de Águas e Energia S.A. (EMAE3.SA) Income Statement Analysis – Financial Results
- Wice Logistics Public Company Limited (WICE.BK) Income Statement Analysis – Financial Results
- Chi Sheng Pharma & Biotech Co., Ltd (4111.TWO) Income Statement Analysis – Financial Results
- DynaColor, Inc. (5489.TWO) Income Statement Analysis – Financial Results
- Grand Ming Group Holdings Limited (1271.HK) Income Statement Analysis – Financial Results
Baudax Bio, Inc. (BXRXQ)
About Baudax Bio, Inc.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Source: https://incomestatements.info
Category: Stock Reports